Oncotarget

Research Papers:

Translocation of heme oxygenase-1 contributes to imatinib resistance in chronic myelogenous leukemia

Bianca Schaefer and Soenke Behrends _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:67406-67421. https://doi.org/10.18632/oncotarget.18684

Metrics: PDF 607 views  |   HTML 1121 views  |   ?  


Abstract

Bianca Schaefer1 and Soenke Behrends1

1Department of Pharmacology, Toxicology and Clinical Pharmacy, University of Braunschweig - Institute of Technology, Braunschweig, 38106, Germany

Correspondence to:

Soenke Behrends, email: s.behrends@tu-braunschweig.de

Keywords: heme oxygenase-1, nuclear translocation, drug resistance, chronic myelogenous leukemia, imatinib

Received: December 01, 2016    Accepted: May 23, 2017    Published: June 27, 2017

ABSTRACT

Heme oxygenase-1 (HO-1) degrades heme to bilirubin. In addition, it is upregulated in malignant disease and has been described as an important factor for cancer prognosis and therapy. Under physiological conditions HO-1 is anchored to the endoplasmic reticulum (ER). Under stress conditions HO-1 can be cleaved and subsequently translocates to the cytosol and nucleus.

In this study we systematically investigated the influence of HO-1’s catabolic activity and subcellular localization on resistance against the tyrosine kinase inhibitor imatinib in leukemia cells by confocal laser scanning microscopy, hemoglobin synthesis experiments and cell viability assays. We created two types of monoclonal K562 cell lines stably transfected with GFP-tagged HO-1: cell lines expressing ER anchored HO-1 or anchorless HO-1. Since translocation of HO-1 disrupts the association with cytochrome P450 reductase, heme degrading activity was higher for ER anchored versus anchorless HO-1. Cell viability tests with increasing concentrations of imatinib showed IC50-values for all six cell lines with ER localized HO-1 that were similar to control cells. However, out of the seven cell lines with anchorless HO-1, two showed a statistically significant increase in the imatinib IC50 (19.76 μM and 12.35 μM versus 2.35 – 7.57 μM of sensitive cell lines) corresponding to plasma concentrations outside the therapeutic range.

We conclude that the presence of translocated HO-1 in the cytosol and nucleus supports imatinib resistance while it is not sufficient to cause imatinib resistance in every cell line. In contrast, an increase in ER anchored HO-1 with high heme degrading activity does not contribute to imatinib resistance.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18684